Compare Arko Corp. (ARKO) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Citius Pharmaceuticals Inc — how do they compare? Arko Corp. trades at $4.37 (market cap $493.06M), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Arko Corp. is far larger — about 24.6× Citius Pharmaceuticals Inc's market cap, and Arko Corp. pays a 2.73% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ARKO | CTXR | |
|---|---|---|
Market Cap | $493.06M | $20.01M |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $1.82 |
52-Week Low | $3.82 | $0.48 |
Enterprise Value | $2.67B | $16.23M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.51, down 4.04% amid a bearish technical trend. The stock shows mixed fundamentals: revenue declined to $7.64B in 2025, but net income improved to $22.74M. Recent Q2 2026 earnings missed estimates, with EPS of $0.04 versus $0.15 expected. The company maintains a dividend, paying $0.03 per share semi-annually, and holds a low P/S ratio of 0.06, though the P/E is elevated at 54.94. Analyst sentiment is neutral with all three covering analysts rating it Hold.
Outlook remains cautious due to declining revenue trends and competitive pressures in the convenience store sector. The stock's low price near recent support levels may attract value investors, but risks include volatile fuel margins and high debt. Institutional interest is present, with Dimensional Fund Advisors increasing its stake by 7.3% in Q2 2026.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
